Home / Deep Research / Acute Annular Outer Retinopathy

Acute Annular Outer Retinopathy

1. Disease Information

2026-05-04
Falcon MONDO:0017299 Model: Edison Scientific Literature 23 citations

1. Disease Information

1.1 What is the disease?

Acute annular outer retinopathy (AAOR) is a rare acute-onset outer retinal disorder characterized clinically by an annular peri-/peripapillary gray-white ring or demarcation line and sudden onset of a scotoma, with evidence of outer retinal disruption on multimodal testing. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3, fekrat2000acuteannularouter pages 1-4)

Authoritative description (primary literature): In the original AAOR case report, a “23-year-old man developed a rapid-onset, large, dense scotoma … associated with a peculiar gray intraretinal ring corresponding to the edge of the scotoma”. (donald1995acuteannularouter pages 1-3)

1.2 Key identifiers (OMIM, Orphanet, ICD-10/11, MeSH, MONDO)

From the retrieved full-text evidence set, no OMIM, Orphanet, ICD-10/ICD-11, MeSH, or MONDO identifiers were explicitly provided; therefore these identifiers cannot be reliably populated from current evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3, donald1995acuteannularouter pages 1-3, fekrat2000acuteannularouter pages 1-4)

1.3 Common synonyms / alternative names

Synonyms and near-synonyms appearing across sources include: - Acute annular outer retinopathy (AAOR) (preferred) (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3) - Acute annular outer retinopathy as a variant of AZOOR (formulation used in classic title/description) (donald1995acuteannularouter pages 1-3) - In some review contexts, AAOR is discussed as an AZOOR-complex/AZOOR-variant entity. (interlandi2023acuteonsetretinalconditions pages 10-11)

1.4 Evidence source type

Evidence is primarily individual patient-level clinical observations (case reports and small case series) aggregated secondarily in reviews. (fekrat2000acuteannularouter pages 1-4, tang2008associationofantiretinal pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11)

2. Etiology

2.1 Disease causal factors (current understanding)

AAOR’s etiology remains unknown in primary reports, with leading hypotheses centered on immune-mediated and/or post-viral processes.

2.2 Risk factors

No validated, quantified risk factors are established in the retrieved evidence. Demographic patterns suggested by AZOOR-complex literature (young women) may apply broadly, but AAOR itself has been described in both sexes and across a wide age range in case series. (fekrat2000acuteannularouter pages 1-4, interlandi2023acuteonsetretinalconditions pages 10-11)

2.3 Protective factors

No protective factors were identified in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, fekrat2000acuteannularouter pages 1-4)

2.4 Gene–environment interactions

No gene–environment interactions are reported for AAOR in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)

3. Phenotypes

3.1 Core symptoms and signs (with ontology suggestions)

AAOR typically presents with acute or subacute visual field symptoms and photopsias, with variable central acuity depending on foveal involvement.

Symptoms / functional phenotypes - Photopsia (HPO: Photopsia HP:0001133) (simunovic2010acuteannularouter pages 1-2, gupta2022acuteannularouter pages 1-3) - Scotoma / visual field defect (HPO: Scotoma HP:0000575) (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3) - Enlarged blind spot (HPO: Enlarged blind spot HP:0031796) (gupta2022acuteannularouter pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11) - Reduced color vision (HPO: Abnormality of color vision HP:0000551) reported in a 2022 case (gupta2022acuteannularouter pages 1-3)

Ocular examination features - Relative afferent pupillary defect (RAPD) (HPO: Relative afferent pupillary defect HP:0030407) described in AAOR/AZOOR variant discussions and cases (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3) - Minimal/no vitreous inflammation (HPO approximation: Absent vitreous inflammation; not a standard HPO term—record clinically as “no vitreous cells/haze”) (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)

3.2 Imaging phenotypes (multimodal)

AAOR is defined largely by multimodal imaging patterns: - Fundus: peri-/papillocentric gray-white ring/demarcation line (interlandi2023acuteonsetretinalconditions pages 10-11, simunovic2010acuteannularouter pages 1-2) - Fundus autofluorescence (FAF): annular hyperautofluorescent border with patchy hypoautofluorescent atrophy zones in a 2022 report (gupta2022acuteannularouter pages 1-3) and hyperfluorescent peripapillary spots in 2010 report (simunovic2010acuteannularouter pages 1-2) - OCT: ellipsoid zone/photoreceptor layer loss within the affected annulus; nodular RPE hyperreflectivity/disruption described in 2022 case (gupta2022acuteannularouter pages 1-3)

Visual evidence (fundus/OCT/FAF) from Gupta et al., 2022: fundus, OCT, and FAF figures showing the characteristic annular lesion pattern were retrieved. (gupta2022acuteannularouter media 9510383f, gupta2022acuteannularouter media 0cc2fd2b, gupta2022acuteannularouter media 8798eaea)

3.3 Age of onset, severity, progression

3.4 Quality of life impact

No formal QoL instruments (e.g., EQ-5D, VFQ-25) were reported in the retrieved evidence. Impact is inferred to be driven by persistent scotomas and/or central vision loss when the fovea is involved. (gupta2022acuteannularouter pages 1-3, donald1995acuteannularouter pages 1-3)

4. Genetic / Molecular Information

4.1 Causal genes and pathogenic variants

No AAOR-specific causal genes, pathogenic variants, or Mendelian inheritance patterns were reported in the retrieved evidence set. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3, fekrat2000acuteannularouter pages 1-4)

4.2 Modifier genes / epigenetics / chromosomal abnormalities

No evidence found in the retrieved sources. (interlandi2023acuteonsetretinalconditions pages 10-11)

Interpretation: AAOR is treated in the literature as an acquired outer retinopathy within the AZOOR spectrum rather than a heritable monogenic disease. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)

5. Environmental Information

5.1 Environmental and lifestyle factors

No established lifestyle or toxin exposures are implicated in the AAOR reports within the retrieved evidence. (fekrat2000acuteannularouter pages 1-4, gupta2022acuteannularouter pages 1-3)

5.2 Infectious agents

Direct infectious causation is unproven; however, herpetic etiologies have been considered in some reports and viral illness is hypothesized as a trigger in immune-mediated models.

A 2010 case report notes no serologic evidence of recent infection with multiple viruses tested: “no serological evidence of recent infection with HSV, HZV, EBV, CMV, Coxsackie virus or echovirus”. (simunovic2010acuteannularouter pages 1-2)

6. Mechanism / Pathophysiology

6.1 Current mechanistic model (causal chain)

A working model supported by clinical course and multimodal imaging is: 1) Trigger (hypothesized viral exposure and/or autoimmune/paraneoplastic immune activation) → 2) Immune-mediated injury to outer retina/photoreceptors (outer retinal dysfunction evidenced by scotoma, mfERG abnormalities) → 3) Structural photoreceptor/ellipsoid zone loss (OCT) and RPE changes/atrophy (FAF and later pigmentary changes) → 4) Persistent scotoma and potential secondary pigment migration/bone-spicule changes. (donald1995acuteannularouter pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3)

6.2 Immune system involvement and antiretinal antibodies

Evidence supporting immune involvement includes: - “immune ring phenomenon” speculation in classic report (donald1995acuteannularouter pages 1-3) - ANA positivity in a case with systemic symptoms (simunovic2010acuteannularouter pages 1-2) - Antiretinal antibodies: a 2008 case series reported indirect immunohistochemistry evidence where “positive reactivity was detected along the inner nuclear layers and nerve fiber layers… [and] very faint staining … along the outer nuclear layers,” while “no reactivity was seen in controls”. (tang2008associationofantiretinal pages 1-3)

6.3 Candidate pathways / processes and ontology suggestions

Because AAOR lacks molecular profiling in the retrieved evidence, pathway mapping is necessarily hypothesis-driven.

Suggested GO Biological Process terms (hypothesis-aligned): - GO:0006955 immune response - GO:0002250 adaptive immune response - GO:0006915 apoptotic process (outer retinal degeneration) - GO:0030198 extracellular matrix organization (for scarring/subretinal fibrosis described in some cases) (fekrat2000acuteannularouter pages 5-8)

Suggested Cell Ontology (CL) terms (site of injury/involvement): - CL:0000210 photoreceptor cell (rods/cones) - CL:0000134 retinal pigment epithelial cell

7. Anatomical Structures Affected

7.1 Organ / tissue level

7.2 Tissue and cell level (with Uberon suggestions)

Suggested UBERON terms (approximate): - UBERON:0000966 retina - UBERON:0001960 retinal pigment epithelium

7.3 Localization and laterality

8. Temporal Development

8.1 Onset pattern

AAOR is characteristically acute onset with possible progression for ~weeks. The original case had “progressive enlargement … for three weeks” before stabilization. (donald1995acuteannularouter pages 1-3)

8.2 Progression and stages (practical staging)

A pragmatic staging consistent with case descriptions: - Acute phase: visible gray-white annular ring/demarcation; expanding scotoma; mfERG abnormalities (donald1995acuteannularouter pages 1-3, tang2008associationofantiretinal pages 1-3) - Subacute: ring fades/disappears; scotoma stabilizes or partially improves (interlandi2023acuteonsetretinalconditions pages 10-11, simunovic2010acuteannularouter pages 1-2) - Chronic: RPE atrophy, pigment migration, possible bone-spicule pigment clumping; persistent scotoma (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)

9. Inheritance and Population

9.1 Epidemiology

No incidence or prevalence estimates were found in the retrieved full-text evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3)

Case counts/statistics available from the evidence set: - A 2000 case series reported 4 patients (2 women aged 29 and 32; 2 men aged 71 and 79). (fekrat2000acuteannularouter pages 1-4) - A 2022 case report states: “There are only 13 cases that have been reported in the literature to date.” (gupta2022acuteannularouter pages 1-3)

9.2 Inheritance

No inherited pattern is supported by the retrieved literature; AAOR is presented as an acquired condition. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)

10. Diagnostics

10.1 Clinical tests and imaging (current real-world implementation)

AAOR diagnosis is primarily clinical and imaging-based.

Multimodal imaging is central: A 2023 review describes AAOR as “characterized by a peri-papillary gray-white ring, disruption of the outer retina within the affected area, and sudden onset of a scotoma” and illustrates a multimodal package: ultra-widefield autofluorescence hyperautofluorescent ring, OCT photoreceptor layer loss, FA hyperfluorescent annulus, and ICGA mild peripapillary hypofluorescence. (interlandi2023acuteonsetretinalconditions pages 10-11)

Functional testing - Visual fields (Goldmann/Humphrey) to document blind spot enlargement/scotomas (gupta2022acuteannularouter pages 1-3, tang2008associationofantiretinal pages 1-3) - Electrophysiology: mfERG depression supporting outer retinal dysfunction (tang2008associationofantiretinal pages 1-3, simunovic2010acuteannularouter pages 1-2)

Laboratory evaluation (rule-out and association workup) Case-based workups often include infectious serologies (herpes viruses, HIV, etc.), autoimmune markers, and systemic evaluation for malignancy when clinically indicated. (simunovic2010acuteannularouter pages 1-2, tang2008associationofantiretinal pages 1-3, gupta2022acuteannularouter pages 1-3)

10.2 Differential diagnosis

AAOR (and AZOOR spectrum conditions) may be mistaken for neuro-ophthalmic disease (optic neuritis) because RAPD can occur and fundus findings may be subtle early; a 2023 review emphasizes this misdiagnosis risk and the need for multimodal retinal imaging. (interlandi2023acuteonsetretinalconditions pages 10-11)

Other retinal acute-onset entities considered in differential (as part of broader acute-onset retinal disorders) include AMN/PAMM and other AZOOR-complex entities. (interlandi2023acuteonsetretinalconditions pages 10-11)

10.3 Genetic testing

No AAOR-directed genetic testing approach is suggested by the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11)

11. Outcome / Prognosis

Prognosis is variable. - Stabilization can occur after an initial expansion phase: “progressive enlargement … for three weeks … followed by stabilization”. (donald1995acuteannularouter pages 1-3) - Structural and pigmentary sequelae can occur: “Development of pigmentary changes in the form of bone spicules was noted after a year within the affected area”. (interlandi2023acuteonsetretinalconditions pages 10-11) - Severe vision loss is possible when the lesion crosses the fovea; in the 2022 case, high-dose prednisone was started but visual acuity worsened to 20/400 and later 20/500/count-fingers during rapid progression. (gupta2022acuteannularouter pages 1-3)

No formal survival/mortality outcomes apply, and no prognostic models or biomarkers are validated in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3)

12. Treatment

12.1 Evidence summary

There is no established, evidence-based therapy for AAOR; reported interventions are anecdotal and based on small numbers.

Treatments attempted in case reports/series include: - Observation/no treatment (some cases) (fekrat2000acuteannularouter pages 1-4, interlandi2023acuteonsetretinalconditions pages 10-11) - Systemic corticosteroids: oral prednisone 40 mg daily tapered over months in a 2008 case; subjective improvement in some series; lack of improvement/worsening in a 2022 case despite high-dose prednisone (tang2008associationofantiretinal pages 1-3, fekrat2000acuteannularouter pages 1-4, gupta2022acuteannularouter pages 1-3) - Antivirals: valacyclovir used when necrosis/herpetic disease considered; IV acyclovir used in suspected herpetic etiology in literature summarized by review/series (tang2008associationofantiretinal pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11, fekrat2000acuteannularouter pages 1-4)

12.2 MAXO suggestions

12.3 Clinical trials

No AAOR-specific clinical trials were identified in the retrieved ClinicalTrials.gov results within this session. (interlandi2023acuteonsetretinalconditions pages 10-11)

13. Prevention

No established primary prevention strategies are supported by AAOR-specific evidence. Practical secondary/tertiary prevention is limited to early recognition (to avoid misdiagnosis and unnecessary neurologic workup) and monitoring for progression/complications within the AZOOR spectrum using multimodal imaging and functional testing. (interlandi2023acuteonsetretinalconditions pages 10-11)

14. Other Species / Natural Disease

No naturally occurring AAOR in other species was identified in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11)

15. Model Organisms

No AAOR-specific model organisms or in vitro models were identified in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11)

Recent developments and latest research emphasis (2023–2024)

2023: Multimodal imaging and differential diagnosis integration

A 2023 review on acute-onset retinal conditions that mimic optic neuritis emphasizes AAOR as a rare entity and provides a multimodal imaging framework (ultra-widefield FAF, OCT, FA, ICGA) to detect outer retinal disruption and avoid misdiagnosis as optic neuritis. (Publication date: Sep 2023; URL: https://doi.org/10.3390/jcm12175720) (interlandi2023acuteonsetretinalconditions pages 10-11)

2024

No AAOR-specific 2024 primary sources were retrievable in the current evidence set; recent-year knowledge is therefore represented by 2022–2023 publications and earlier foundational reports. (gupta2022acuteannularouter pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11)

Notes on PMID requirement

Several retrieved PDFs/excerpts did not display PMIDs in the parsed text; therefore citations are provided using DOIs/URLs from the retrieved sources. For strict PMID-only population of a knowledge base, a follow-on PubMed-anchored pass would be needed to map each DOI to its PMID.

Key source URLs (with publication dates)

References

  1. (donald1995acuteannularouter pages 1-3): J. DONALD, M. GASS, and CHARLES STERN. Acute annular outer retinopathy as a variant of acute zonal occult outer retinopathy. American journal of ophthalmology, 119 3:330-4, Mar 1995. URL: https://doi.org/10.1016/s0002-9394(14)71176-6, doi:10.1016/s0002-9394(14)71176-6. This article has 76 citations and is from a domain leading peer-reviewed journal.

  2. (fekrat2000acuteannularouter pages 1-4): Sharon Fekrat, C.P Wilkinson, Benjamin Chang, Lawrence Yannuzzi, Howard Schatz, and Julia A Haller. Acute annular outer retinopathy: report of four cases. American journal of ophthalmology, 130 5:636-44, Nov 2000. URL: https://doi.org/10.1016/s0002-9394(00)00560-2, doi:10.1016/s0002-9394(00)00560-2. This article has 58 citations and is from a domain leading peer-reviewed journal.

  3. (tang2008associationofantiretinal pages 1-3): Johnny Tang, R. Stevens, A. Okada, M. Chin, R. Nussenblatt, and C. Chan. Association of antiretinal antibodies in acute annular outer retinopathy. Archives of ophthalmology, 126 1:130-2, Jan 2008. URL: https://doi.org/10.1001/archophthalmol.2007.5, doi:10.1001/archophthalmol.2007.5. This article has 26 citations.

  4. (simunovic2010acuteannularouter pages 1-2): M P Simunovic, E H Hughes, B S Townend, and I-V Ho. Acute annular outer retinopathy with systemic symptoms. Eye, 24:1125-1126, Jun 2010. URL: https://doi.org/10.1038/eye.2009.252, doi:10.1038/eye.2009.252. This article has 14 citations and is from a peer-reviewed journal.

  5. (gupta2022acuteannularouter pages 1-3): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.

  6. (interlandi2023acuteonsetretinalconditions pages 10-11): Emanuela Interlandi, Francesco Pellegrini, Chiara Giuffrè, Daniele Cirone, Daniele Brocca, Andrew G. Lee, and Giuseppe Casalino. Acute-onset retinal conditions mimicking acute optic neuritis: overview and differential diagnosis. Journal of Clinical Medicine, 12:5720, Sep 2023. URL: https://doi.org/10.3390/jcm12175720, doi:10.3390/jcm12175720. This article has 5 citations.

  7. (gupta2022acuteannularouter media 9510383f): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.

  8. (seetharam2015newinsightsinto pages 1-2): Shabari S. Seetharam, Lee M. Jampol, and Manjot K. Gill. New insights into acute annular outer retinopathy. RETINAL Cases & Brief Reports, 9:1-6, Jan 2015. URL: https://doi.org/10.1097/icb.0000000000000070, doi:10.1097/icb.0000000000000070. This article has 15 citations and is from a peer-reviewed journal.

  9. (gupta2022acuteannularouter media 0cc2fd2b): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.

  10. (gupta2022acuteannularouter media 8798eaea): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.

  11. (fekrat2000acuteannularouter pages 5-8): Sharon Fekrat, C.P Wilkinson, Benjamin Chang, Lawrence Yannuzzi, Howard Schatz, and Julia A Haller. Acute annular outer retinopathy: report of four cases. American journal of ophthalmology, 130 5:636-44, Nov 2000. URL: https://doi.org/10.1016/s0002-9394(00)00560-2, doi:10.1016/s0002-9394(00)00560-2. This article has 58 citations and is from a domain leading peer-reviewed journal.